Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Langenbeck's Archives of Surgery
Published in: Langenbeck's Archives of Surgery 5/2005

01-09-2005 | Original Article

Palliative management strategies of advanced gastrointestinal carcinoid neoplasms

Authors: Paola Sartori, Chiara Mussi, Carlo Angelini, Stefano Crippa, Roberto Caprotti, Franco Uggeri

Published in: Langenbeck's Archives of Surgery | Issue 5/2005

Login to get access

Abstract

Background/aims

Optimal management of gastrointestinal carcinoid neoplasms that metastasize to the liver is controversial. Although operative resection seems to be the most effective approach to metastatic disease, hepatic metastases are usually multicentric and often non-resectable. We investigated the effectiveness of several forms of palliative tumor cytoreduction followed by administration of somatostatin analogues in advanced carcinoid neoplasms.

Methods

We reviewed our experience with 34 patients with gastrointestinal carcinoid neoplasms. Eighteen patients had metastases and 14 had hormonal symptoms. Twenty-two patients underwent radical surgery, ten with multiple liver metastases were treated with a combination of debulking (resection, radiofrequency ablation, chemoembolization), followed by medical treatment with long-acting octreotide and eventually by radiolabelled somatostatin analogues, and two patients with intractable disease received only biotherapies.

Results

The six patients with metastatic disease who underwent radical curative liver resection had a median survival of 52 months, compared with a median survival of 48 months in the ten patients who underwent palliative debulking. Symptomatic improvement was observed in all the patients after debulking procedures. The two patients who underwent only medical treatment died after 9 and 18 months.

Conclusions

Aggressive tumor debulking should be performed in patients with liver metastases already at diagnosis even when complete resection is not feasible because the combination of cytoreductive procedures followed by biotherapies may provide good long-term survival and achieves symptom control in most patients with advanced disease.
Literature
1.
Bax NSD, Woods HF, Batchelor A, Jennings M (1996) Clinical manifestations of carcinoid disease. World J Surg 20(2):142–146CrossRefPubMed
2.
McDermott EW, Guduric B, Brennan MF (1994) Prognostic variables in patients with gastrointestinal carcinoid tumors. Br J Surg 81:1007–1009PubMed
3.
Norton JA, Warren RS, Kelly MG, Zuraek B, Jensen RT (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134:1057–1065CrossRefPubMed
4.
Nave H, Mossinger E, Feist H, Lang H, Raab H-R (2001) Surgery as primary treatment in patients with liver metastases from carcinoid tumors : a retrospective, unicentric study over 13 years. Surgery 129:170–175CrossRefPubMed
5.
Que FG, Sarmiento JM, Nagorney DM (2002) Hepatic surgery for metastatic gastrointestinal endocrine tumors. Cancer Control 9(1):67–79PubMed
6.
Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37CrossRefPubMed
7.
O’ Toole D, Maire F, Ruszniewki P (2003) Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 10:463–468CrossRefPubMed
8.
Schell SR, Ramsay Camp E, Caridi JG (2002) Hepatic artery embolization for control of symptoms, octreotide requirements and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6:664–670CrossRefPubMed
9.
Hellmann P, Ladjevardi S, Skogseid B, Akestrom G, Elvin A (2002) Radio-frequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26:1052–1056CrossRefPubMed
10.
Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F (2001) Receptor-mediated radiotherapy with 90 Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 28(4):426–434
11.
Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G (1995) Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch 425(6):547–560PubMed
12.
Solcia E, Kloppel G, Sobin L (2000) Histological typing of endocrine tumors. In: WHO international histological classification of tumors, 2nd edn. Springer, Berlin Heidelberg New York, pp 56–74
13.
Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Macke HR, Chinol M, Paganelli G (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with aminoacidic infusion: a phase 1 study. Eur J Nucl Med 30:207–216
14.
Solcia E, Fiocca R, Rindi G, Villani L, Cornaggia M, Capella C (1993) The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 22:795–821PubMed
15.
Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y (1996) Metastatic endocrine tumors: medical treatment, surgical resection or liver transplantation. World J Surg 20:908–915CrossRefPubMed
16.
Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion 68(2–3):94–101CrossRefPubMed
17.
Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9(4):261–267PubMed
18.
Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, Lasser P, Schlumberger M, Duceux M (2003) Trans-catheter chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13(1):136–140PubMed
19.
Berber E, Siperstein AE (2003) Laparoscopic radio-frequency ablation of neuroendocrine liver metastases. Probl Gen Surg 20(3):134–142CrossRef
20.
Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K (1997) Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogues. Acta Oncol 36:607–614PubMed
21.
Sharma H, Patel YC, Srikant CB (1996) Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688–1696CrossRefPubMed
22.
Leong WL, Pasieka JL (2002) Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and review of the literature. J Surg Oncol 79:180–187CrossRefPubMed
23.
Wilander E, Bengtsson A, Norheim I, Oberg K (1986) Interferon induced nuclear DNA alteration in malignant carcinoid tumours in vivo. J Natl Cancer Inst 76:429–433PubMed
24.
Andersson T, Wilander E, Eriksson B, Lindgren PG, Oberg K (1990) Effects of interferons on tumor tissue content in liver metastases of carcinoid tumors. Cancer Res 50:3413PubMed
25.
Oberg K, Eriksson B, Janson ET (1994) The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Ann N Y Acad Sci 733:471–478
26.
Tiensuu-Janson EM, Ahlstrom H, Andersson T, Oberg K (1992) Octreotide and interferon-alpha: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28:1647–1650CrossRef
27.
Janson ET, Oberg K (1993) Long-term management of carcinoid syndrome. Treatment with octreotide alone and in combination with alpha interferon. Acta Oncol 32:225–229
28.
Nold R, Frank K, Kajdan U, Trost U, Klose KJ, Arnold R (1994) Combined treatment of metastatic endocrine tumors of gastrointestinal tract with octreotide and interferon-alpha. Z Gastroenterol 32:193–197
29.
Kaidan U, Frank K, Elhenz K, Arnold R (1995) Effect of alpha-interferon plus octreotide on metastasized gastrointestinal endocrine tumours. Gut 37(2):A255–A256. Abstract 2283
30.
Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, Bilchik AJ (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130:954–962CrossRefPubMed
31.
Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine (131I-mIBG). Clin Endocrinol 55:47–60CrossRef
32.
Hoefnagel CA (1994) Meta-iodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 21:561–581PubMed
33.
Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH (1996) Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumours. J Clin Oncol 14:1829–1838PubMed
Metadata
Title
Palliative management strategies of advanced gastrointestinal carcinoid neoplasms
Authors
Paola Sartori
Chiara Mussi
Carlo Angelini
Stefano Crippa
Roberto Caprotti
Franco Uggeri
Publication date
01-09-2005
Publisher
Springer-Verlag
Published in
Langenbeck's Archives of Surgery / Issue 5/2005
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-005-0559-2

Other articles of this Issue 5/2005

Langenbeck's Archives of Surgery 5/2005 Go to the issue

How To Do It

Pylorus-preserving gastrectomy in gastric cancer surgery—open and laparoscopic approaches

Original Article

Impaired expression of hepatic multidrug resistance protein 2 is associated with posthepatectomy hyperbilirubinemia in patients with biliary cancer

Original Article

Risk factors influencing the early outcome results after laparoscopic repair of perforated duodenal ulcer and their predictive value

Original Article

A less invasive, selective, functional neck dissection for papillary thyroid carcinoma

Current Concepts in Clinical Surgery

Laparoscopic cholecystectomy in acute cholecystitis: indication, technique, risk and outcome

Original Article

Results of iterative surgery for persistent and recurrent parathyroid carcinoma